A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis

Trial Profile

A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms SIMPLIFY
  • Sponsors Biogen
  • Most Recent Events

    • 06 Jul 2015 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016, according to ClinicalTrials.gov record.
    • 06 Jul 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016, according to ClinicalTrials.gov record.
    • 06 Jul 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top